2257-69-4

Basic information

• Product Name: 4-CHLORO-1,2-DIHYDROPHTHALAZIN-1-ONE
• Synonyms: AURORA KA-6768;4-CHLORO-1,2-DIHYDROPHTHALAZIN-1-ONE;1-Chlorophtalazin-4-one;1-CHLOROPHTHALAZIN-4-ONE;1-CHLORO-4-PHTHALAZINONE;4-Chloro-1(2H)-phthalazinone, 98%;1-Chloro-3,4-dihydrophthalazin-4-one;4-chlorophthalazin-1(2H)-one
• CAS NO: 2257-69-4
• Molecular Formula: C₈H₅ClN₂O
• Molecular Weight: 180.59
• Mol File: 2257-69-4.mol

Chemical Properties

• Melting Point: 273 °C
• Boiling Point: 452.7 °C at 760 mmHg
• Flash Point: 227.6 °C
• Appearance: /
• Density: 1.5 g/cm³
• Vapor Pressure: 8.2E-09mmHg at 25°C
• Refractive Index: 1.688
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.58±0.40(Predicted)
• CAS DataBase Reference: 4-CHLORO-1,2-DIHYDROPHTHALAZIN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-1,2-DIHYDROPHTHALAZIN-1-ONE(2257-69-4)
• EPA Substance Registry System: 4-CHLORO-1,2-DIHYDROPHTHALAZIN-1-ONE(2257-69-4)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• Hazardous Substances Data: 2257-69-4(Hazardous Substances Data)

Usage

Uses

1-Chlorophthalazin-4-one acts as an organic and pharmaceutical intermediate.

InChI:InChI=1/C8H5ClN2O/c9-7-5-3-1-2-4-6(5)8(12)11-10-7/h1-4H,(H,11,12)

Upstream product

• 4752-10-7 1,4-dichlorophthalazine 
• 88-99-3 benzene-1,2-dicarboxylic acid 
• 87878-22-6 2-phenyl-4-(2-methyl-4-chloro-1,2-dihydro-1-phthalazinylidene)benzohydrazidine 
• 7647-01-0 hydrogenchloride 
• 4397-55-1 phthalic monoacid monomethyl ester chloride 
• 1445-69-8 2,3-dihydrophthalazine-1,4-dione 
• 85-44-9 phthalic anhydride 
• 1875-48-5 N-aminophthalamide 
• 4388-29-8 [2,2'-biisoindoline]-1,1',3,3'-tetraone 
• 136918-14-4 phthalimide 

Downstream Products

• 78755-14-3 4-pyrrolidino-1-(2H)-phthalazinone 
• 69776-14-3 phthalazonyl glycol ether 
• 78755-15-4 4-piperidino-1(2H)-phthalazinone 
• 78755-20-1 4-morpholino-1(2H)-phthalazinone 
• 78755-23-4 4-heptamethyleneimino-1(2H)-phthalazinone 
• 78755-19-8 4-(3,5-dimethylpiperidino)-1(2H)-phthalazinone 
• 78755-24-5 4-octamethyleneimino-1(2H)-phthalazinone 
• 78755-21-2 4-(2,6-dimethylmorpholino)-1(2H)-phthalazinone 
• 78755-16-5 4-(4-methylpiperidino)-1(2H)-phthalazinone 
• 78755-22-3 4-hexamethyleneimino-1(2H)-phthalazinone 
• 78755-27-8 4-(N-methylcyclohexylamino)-1(2H)-phthalazinone 
• 13580-91-1 4-(phenylamino)phthalazin-1(2H)-one 
• 40227-54-1 4-chloro-2-methylphthalazin-1-(2H)-one 
• 78755-18-7 4-(2-methylpiperidino)-1(2H)-phthalazinone 

Relevant articles and documents

Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors

HBV capsid assembly has been viewed as an attractive target for new antiviral therapies against HBV. On the basis of a lead compound 4r, we further investigated this target to identify novel active compounds with appropriate anti-HBV potencies and improved pharmacokinetic (PK) properties. Structure-activity relationship studies based on metabolic pathways of 4r led to the identification of a phthalazinone derivative 19f with appropriate anti-HBV potencies (IC50 = 0.014 ± 0.004 μM in vitro), which demonstrated high oral bioavailability and liver exposure. In the AAV-HBV/mouse model, administration of 19f resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment with 150 mg/kg dosing twice daily.

4-pyridine substituted phthalazinone compound as well as preparation method, pharmaceutical composition and application thereof

The invention relates to a 4-pyridine substituted phthalazinone compound, a preparation method, a pharmaceutical composition and an application thereof, the structure of the 4-pyridine substituted phthalazinone compound is shown as a formula I, the compound of the formula I has improved pharmaceutical physicochemical properties and in-vivo pharmacokinetic properties, oral bioavailability is high,druggability is good, The compound is a non-nucleoside small-molecule HBV virus inhibitor which is novel in structure and can be orally taken.

Phthalazinone compound and preparation method, pharmaceutical composition and use thereof

The invention relates to a phthalazinone compound and a preparation, pharmaceutical composition and use thereof, wherein the structure of the phthalazinone compound is shown as formula one, and the compound of the formula one is targeted to a virus nuclea

Pyridazinone compound, preparation method thereof, pharmaceutical composition and application thereof

The invention relates to a pyridazinone compound shown as a formula I or an isomer thereof, or a pharmaceutically acceptable salt, ester, a prodrug or a solvate thereof, a preparation method thereof,a pharmaceutical composition and an application of the pharmaceutical composition for preparing a dengue virus inhibitor. The pyridazinone compound has a structure shown in the formula I. The compoundor the pharmaceutical composition thereof has anti-dengue virus activity and better selectivity, and can be used for preventing and/or treating dengue virus infection.

TOLL-LIKE RECEPTOR 8 (TLR8)-SPECIFIC ANTAGONISTS AND METHODS OF MAKING AND USES THEREOF

Toll-like receptor 8 (TLR8)-specific inhibitors and methods of using the same in individuals having an autoimmune disease or an inflammatory disorder.

Discovery and optimization of phthalazinone derivatives as a new class of potent dengue virus inhibitors

Using a dengue replicon cell line-based screening, we identified 3-(dimethylamino)propyl(3-((4-(4-fluorophenyl)-1-oxophthalazin-2(1H)-yl)methyl)phenyl)carbamate (10a) as a potent DENV-2 inhibitor, with an IC50 value of 0.64 μM. A series of novel phthalazinone derivatives based on hit 10a were synthesized and evaluated for their in vitro anti-DENV activity and cytotoxicity. The subsequent SAR study and optimization led to the discovery of the most promising compound 14l, which displayed potent anti-DENV-2 activity, with low IC50 value against DENV-2 RNA replication of 0.13 μM and high selectivity (SI = 89.2) with acceptable pharmacokinetics profiles.

Synthetic method of olaparib

The invention discloses a synthetic method of olaparib. The synthetic method comprises the following steps: with phthalhydrazide as a starting material, reacting with phosphorus oxychloride to generate 1-chloro-4-carbonylpyridazine, and further reacting with ethyl 2-fluoro-5-bromomethylbenzoate, so as to generate ethyl 2-fluoro-5-[(4-carbonyl-3,4-dihydropyridazin-1-yl)methyl]benzoate; and carryingout hydrolysis and acylation, and carrying out condensation reaction by virtue of ethyl 2-fluoro-5-[(4-carbonyl-3,4-dihydropyridazin-1-yl)methyl]benzoate and 1-(cyclopropylcarbonyl)-piperazine, so asto generate olaparib. The synthetic method has the beneficial effects that phthalhydrazide is taken as the starting material for the first time, is easily available and is environmentally friendly; by utilizing Neigishi coupling, organic metal is utilized for reaction, catecholborane with a relatively high cost is not used, and zinc powder is used, so that the production cost is lowered, and thetotal yield of the route reaches 70.2%; and the reaction route is relatively short, reaction conditions are mild, and the synthetic method is suitable for industrial production.

HYDRAZONES OF PHTHALAZONES. SOME FORMAZANS AND HYDRAZIDINES

In formazans, isolated during the azo coupling of arenediazonium salts with benzylidenehydrazones of 4-chloro-1-phthalazinone, the hydrogen atom is localized at the nitrogen atom of the ring and not in the formazan fragment.These formazans and their analo